Van Herk Investments notify of 5.3% shareholding in Galapagos
Mechelen, Belgium; 6 January 2014 - Galapagos NV (Euronext: GLPG) received
notice that Van Herk Investments currently holds 5.3% of outstanding Galapagos
shares.
Pursuant to Belgian transparency legislation[1], Galapagos received notice on
31 December 2013 from Van Herk Investments B.V., stating that they held
1,586,727 shares. This represents 5.3% of the 29,794,046 Galapagos shares
currently outstanding and marks the first transparency notice that Galapagos has
received from Van Herk Investments.
About Van Herk Investments
Part of the Van Herk Group of companies, Van Herk Investments is invested in
listed and private companies. Â Van Herk Investments has a global orientation,
with holdings in construction, project development, biotechnology and life
sciences, financial services, and energy sectors. Current biotechnology and
life sciences holdings include Agendia, ART, BioInvent, CardioGenX, Galapagos,
Nightbalance, SkylineDx and VitalNext. More information at www.vanherkgroep.nl
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising of six Phase 2 studies (three led by GSK), one
Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and
other indications.
AbbVie and Galapagos signed an agreement in CF where they work collaboratively
to develop and commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. Potentiator GLPG1837 is at the pre-
clinical candidate stage. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be responsible for
further development and commercialization of GLPG0634 after Phase 2B. GLPG0634
is an orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease.
Galapagos has another selective JAK1 inhibitor in Phase 2 in ulcerative colitis,
psoriasis, and lupus, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is currently in a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and has completed Phase 1 studies.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information, including
an updated major shareholder overview, can be found at: www.glpg.com
Contact
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
--------------------------------------------------------------------------------
[1] Â Â Â Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market.
Van Herk Investments notify of 5.3% shareholding in Galapagos:
http://hugin.info/133350/R/1752896/591125.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1752896]